- Home
- OMER vs LVWR Comparison
OMER vs LVWR Comparison
Compare OMER & LVWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- LVWR
- Stock Information
- Founded
- OMER 1994
- LVWR 2022
- Country
- OMER United States
- LVWR United States
- Employees
- OMER N/A
- LVWR N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- LVWR
- Sector
- OMER Health Care
- LVWR
- Exchange
- OMER Nasdaq
- LVWR Nasdaq
- Market Cap
- OMER 188.1M
- LVWR 205.6M
- IPO Year
- OMER 2009
- LVWR N/A
- Fundamental
- Price
- OMER $3.65
- LVWR $3.45
- Analyst Decision
- OMER Strong Buy
- LVWR
- Analyst Count
- OMER 5
- LVWR 0
- Target Price
- OMER $18.00
- LVWR N/A
- AVG Volume (30 Days)
- OMER 936.6K
- LVWR 622.0K
- Earning Date
- OMER 08-06-2025
- LVWR 07-24-2025
- Dividend Yield
- OMER N/A
- LVWR N/A
- EPS Growth
- OMER N/A
- LVWR N/A
- EPS
- OMER N/A
- LVWR N/A
- Revenue
- OMER N/A
- LVWR $24,398,000.00
- Revenue This Year
- OMER N/A
- LVWR $249.13
- Revenue Next Year
- OMER $468.75
- LVWR $98.53
- P/E Ratio
- OMER N/A
- LVWR N/A
- Revenue Growth
- OMER N/A
- LVWR N/A
- 52 Week Low
- OMER $2.95
- LVWR $0.93
- 52 Week High
- OMER $13.60
- LVWR $9.04
- Technical
- Relative Strength Index (RSI)
- OMER 54.74
- LVWR 39.76
- Support Level
- OMER $3.00
- LVWR $3.82
- Resistance Level
- OMER $3.25
- LVWR $4.11
- Average True Range (ATR)
- OMER 0.24
- LVWR 0.44
- MACD
- OMER 0.10
- LVWR -0.27
- Stochastic Oscillator
- OMER 83.33
- LVWR 0.41
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About LVWR LiveWire Group Inc.
LiveWire Group Inc is an all-electric vehicle company. It sells electric vehicles and related parts and accessories and apparel in the United States and certain international markets. The company's segment includes Electric Motorcycles and STACYC. Electric Motorcycles segment sells electric motorcycles, related parts and accessories and apparel in the United States and certain international markets; STACYC segment sells electric balance bikes for kids, related parts and accessories and apparel in the United States and certain international markets. LiveWire generates revenue from the sale of electric motorcycles, Parts, accessories and apparel. Majority of revenue is from USA.